2025 Australasian Ocular Melanoma Alliance (AOMA) Virtual Summit
Date: 8/11/2025 (AEDT)
Venue: Online, VIC, 3004
Provider: Melanoma and Skin Cancer Trials
Contact: Gabrielle Byars, [E] hello@masc.org.au, Website: https://www.masc.org.au/aoma-summit-2025/, [P] +61 3 9903 9022
Activity Outline
The 2025 Australasian Ocular Melanoma Alliance (AOMA) Virtual Summit will bring together healthcare professionals, researchers, and consumers in ocular melanoma to share the latest research and facilitate national and international collaborations for this rare, aggressive, and often devastating cancer.
This free virtual event will feature international and Australian ocular melanoma experts, along with consumers who will present on their experiences with ocular melanoma. The summit will cover the latest in clinical trials, ocular melanoma therapies, advances in ophthalmology, new Australian and international research, radiation oncology, and more.
Learning Objectives
- Understand how a young woman in the prime of her life refused to let her ocular melanoma diagnosis stop her from living a fulfilling life, including starting a family and raising awareness for this rare cancer.
- Understand the challenges regional Australians with ocular melanoma face in accessing diagnosis, treatment, and ongoing care.
- Discuss relating to patient experiences with ocular melanoma including difficulties relating to diagnosis, treatment and care.
- Discuss the potential role of Virus-like Drug Conjugates (VDCs) in treating early-stage choroidal melanoma, with a focus on the data available from the Phase 3 CoMpass trial.
- Describe an overview of the treatment options and clinical approaches for uveal melanoma within the Australian healthcare context
- Describe current ocular melanoma therapies and clinical trials.
- Understand the role of BAP1 gene deficiency in the progression of uveal melanoma, its impact on cancer cell survival under nutrient-deprived conditions and how these findings may inform future therapeutic strategies to prevent or treat metastatic disease.
- Understand how individuals with metastatic uveal melanoma cope with uncertainty in the context of rapidly emerging immunotherapies and targeted treatments.
- Engage in discussions and ask questions relating to the latest Australian ocular melanoma research.
- Differentiate between choroidal naevus and choroidal melanoma based on clinical features, risk factors, and diagnostic criteria to guide appropriate monitoring and referral.
- Understand the role of an ocularist in wholistically working with ocular melanoma patients through their eye loss, the development of an artificial eye, and living with this prothesis.
- Engage in discussions and ask questions relating to Ophthalmology.
- Understand the clinical outcomes and use of stereotactic radiotherapy treatment in posterior choroidal melanoma.
- Understand the principles and clinical application of eye plaque brachytherapy; the limitations and common toxicities of eye plaque brachytherapy; and the effectiveness of eye plaque brachytherapy in the treatment of ocular melanoma.
- Engage in discussions and ask questions relating to radiation oncology for treatment of ocular melanoma.
- Discuss the prompt diagnosis of Choroidal Melanoma covering clinical aspects, ancillary testing and the future use of artificial intelligence in the field.
Max CPD hours awarded: 4.25
Session Information
| Name |
|---|
| Virus-like Drug Conjugates (VDCs) as first-line treatment of early-stage choroidal melanoma. |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| No |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Uveal melanoma: Australian treatment landscape |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| No |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Ocular melanoma therapies and clinical trials Q&A facilitated by Dr Li-Anne Lim, Jill Hopkins and Dr Malaka Ameratunga |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Identifying the roles of BAP1 in uveal melanoma |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| No |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Dealing with uncertainty in the context of metastatic uveal melanoma: A qualitative study |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| No |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Latest Australian ocular melanoma research Q&A facilitated by Dr Rod O’Day, Dr Vivian Chua and A/Prof Tim Luckett |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Choroidal naevus vs melanoma |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| No |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| What happens next? |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| No |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Ophthalmology Q & A facilitated by Dr Li-Anne Lim, Rod O’Day, James H Morphett and a consumer from OMie study |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Stereotactic radiotherapy for posterior choroidal melanoma |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| No |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Eye Plaque Brachytherapy treatment in Australia’s Sunshine State |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| No |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
Ophthalmology Q&A facilitated by Dr Li-Anne Lim, Dr Rod O’Day, James H Morphett and a consumer from the OMNi study
|
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| Yes |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| Update on Prompt Diagnosis of Choroidal Melanoma |
| Clinical? |
|---|
| Yes |
| Interactive? |
|---|
| No |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.5 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.5 |
| Name |
|---|
| Now what? Life after eye cancer |
| Clinical? |
|---|
| No |
| Interactive? |
|---|
| No |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| An eye opener - Diagnosis, Distance and Determination |
| Clinical? |
|---|
| No |
| Interactive? |
|---|
| No |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name |
|---|
| AOMA Q&A facilitated by Prof Anthony Joshua, Georgia Hall and Carolyn Alkemade |
| Clinical? |
|---|
| No |
| Interactive? |
|---|
| Yes |
| Therapeutic? |
|---|
| No |
| Duration of CPD Session/Module |
|---|
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
|---|
| 0.25 |
| Name | Clinical? | Interactive? | Therapeutic? | CPD Hours |
|---|
| Virus-like Drug Conjugates (VDCs) as first-line treatment of early-stage choroidal melanoma. | Yes | No | Yes | 0.25 | 0.25 |
| Uveal melanoma: Australian treatment landscape | Yes | No | Yes | 0.25 | 0.25 |
| Ocular melanoma therapies and clinical trials Q&A facilitated by Dr Li-Anne Lim, Jill Hopkins and Dr Malaka Ameratunga | Yes | Yes | Yes | 0.25 | 0.25 |
| Identifying the roles of BAP1 in uveal melanoma | Yes | No | Yes | 0.25 | 0.25 |
| Dealing with uncertainty in the context of metastatic uveal melanoma: A qualitative study | Yes | No | No | 0.25 | 0.25 |
| Latest Australian ocular melanoma research Q&A facilitated by Dr Rod O’Day, Dr Vivian Chua and A/Prof Tim Luckett | Yes | Yes | Yes | 0.25 | 0.25 |
| Choroidal naevus vs melanoma | Yes | No | No | 0.25 | 0.25 |
| What happens next? | Yes | No | No | 0.25 | 0.25 |
| Ophthalmology Q & A facilitated by Dr Li-Anne Lim, Rod O’Day, James H Morphett and a consumer from OMie study | Yes | Yes | No | 0.25 | 0.25 |
| Stereotactic radiotherapy for posterior choroidal melanoma | Yes | No | Yes | 0.25 | 0.25 |
| Eye Plaque Brachytherapy treatment in Australia’s Sunshine State | Yes | No | Yes | 0.25 | 0.25 |
| Radiation Oncology Q&A facilitated by Dr Lotte Fog, A/Prof Claire Phillips and Dr Sarah Li | Yes | Yes | Yes | 0.25 | 0.25 |
| Update on Prompt Diagnosis of Choroidal Melanoma | Yes | No | No | 0.5 | 0.5 |
| Now what? Life after eye cancer | No | No | No | 0.25 | 0.25 |
| An eye opener - Diagnosis, Distance and Determination | No | No | No | 0.25 | 0.25 |
| AOMA Q&A facilitated by Prof Anthony Joshua, Georgia Hall and Carolyn Alkemade | No | Yes | No | 0.25 | 0.25 |